Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03)
Authors:
Open Access
- 6 December 2019
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 28 (8) , 3649-3657
Abstract
Purpose: Capecitabine-based adjuvant chemotherapy for colorectal cancer patients often causes adverse events (AEs), such as diarrhea, stomatitis, anorexia, and hand-foot syndrome (HFS). Cystine and theanine were reported to attenuate some chemotherapy-associated AEs, and hence are also expected to attenuate capecitabine-induced AEs. Therefore, we aimed to investigate the safety and efficacy of cystine/theanine treatment in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery. Methods: A total of 100 colorectal cancer patients treated with capecitabine as an adjuvant chemotherapy after surgery were randomly allocated into the cystine/theanine group (n = 52) or the placebo group (n = 48). The primary endpoint was incidence rate of diarrhea of grade 1 or higher in accordance with the Common Terminology Criteria for AEs (CTCAE) v.4.0, Japanese Clinical Oncology Group (JCOG) version. The secondary endpoints included incidence rates of other AEs (CTCAE v.4.0-JCOG), as well as the incidence rate of HFS according to the HFS grading scale. Results: There were no significant differences in capecitabine-induced AEs between the two groups. However, the incidence rate of diarrhea of grade 1 or higher tended to be lower in the cystine/theanine group than the placebo group (18.4% vs. 28.9%, p = 0.169) as well as the incidence rate of HFS of grade 1 or higher (CTCAE v.4.0-JCOG or HFS grading scale) (67.4% vs. 77.8%, p = 0.185, 67.3% vs. 80.0%, p = 0.124, respectively). Conclusion: This trial demonstrated that cystine/theanine treatment of colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery is safe and has the tendency to reduce the incidence rate of diarrhea or HFS. Trial registration: UMIN000024784Keywords
Funding Information
- Ajinomoto Co., Inc.
This publication has 19 references indexed in Scilit:
- Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: A meta-analysisBiomedical Reports, 2013
- Perioperative Oral Administration of Cystine and Theanine Enhances Recovery After Distal GastrectomyJournal of Parenteral and Enteral Nutrition, 2012
- Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trialAnnals of Oncology, 2011
- The effect of COX-2 inhibitor on capecitabine-induced hand–foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective studyJournal of Cancer Research and Clinical Oncology, 2010
- Co‐administration of l‐cystine and l‐theanine enhances efficacy of influenza vaccination in elderly persons: Nutritional status‐dependent immunogenicityGeriatrics & Gerontology International, 2008
- Randomized, placebo‐controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline‐based chemotherapyCancer, 2007
- Oral Uracil and Tegafur Plus Leucovorin Compared With Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project Protocol C-06Journal of Clinical Oncology, 2006
- Capecitabine as Adjuvant Treatment for Stage III Colon CancerNew England Journal of Medicine, 2005
- Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled TrialJournal of Clinical Oncology, 2002
- Antineoplastic Therapy???Induced Palmar Plantar Erythrodysesthesia (???Hand-Foot???) SyndromeAmerican Journal of Clinical Dermatology, 2000